Stayble Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, revenue was SEK 0.006 million compared to SEK 0.222 million a year ago. Net loss was SEK 10.41 million compared to SEK 14.08 million a year ago. Basic loss per share from continuing operations was SEK 0.53 compared to SEK 1.02 a year ago.